SCHEMBL102971

SCHEMBL102971

CC(=O)c1ccc2c(c1)OCCO2

nearest known ligand 0.89

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.89
TSHR P16473 3/20 0.67
ATM Q13315 1/20 0.66
POLB P06746 1/20 0.62
HPGD P15428 2/20 0.62
NPSR1 Q6W5P4 2/20 0.61
CYP1A2 P05177 1/20 0.61
CYP2C19 P33261 1/20 0.61
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
CTNNB1 P35222 2/20 0.58
WNT3A P56704 1/20 0.58
KMT2A Q03164 2/20 0.57
MAPT P10636 2/20 0.57
LMNA P02545 1/20 0.57
PKM P14618 1/20 0.57
MEN1 O00255 1/20 0.56
RECQL P46063 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14849222 0.94 KDM4E (1.00) KDM4ETSHRATMPOLBHPGD
SCHEMBL10031401 0.94 KDM4E (1.00) KDM4ETSHRATMPOLBHPGD
SCHEMBL14937523 0.94 KDM4E (1.00) KDM4ETSHRATMPOLBHPGD
SCHEMBL13596352 0.92 KDM4E (0.77) KDM4ETSHRATMPOLBHPGD
SCHEMBL3735582 0.92 KDM4E (0.77) KDM4ETSHRATMPOLBHPGD
3,4-Methylendioxy Acetophenone SCHEMBL137979 0.88 KDM4E (0.71) KDM4ETSHRHPGDCYP1A2CYP2C19
3,4-Methylendioxy Acetophenone SCHEMBL29405437 0.88 KDM4E (0.71) KDM4ETSHRHPGDCYP1A2CYP2C19
3,4-Methylendioxy Acetophenone SCHEMBL31108909 0.85 KDM4E (0.67) KDM4ETSHRATMPOLBHPGD
SCHEMBL12930767 0.85 KDM4E (0.67) KDM4ETSHRATMPOLBHPGD
SCHEMBL4824992 0.83 NPSR1 (0.74) KDM4ETSHRATMHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3354727-B1 TRANSAMINASE POLYPEPTIDES CODEXIS INC (US) 2020-10-07 EP claimed
US-10052326-B1 Antihepatotoxic agents KING SAUD UNIVERSITY (SA) 2018-08-21 US claimed
EP-3354727-A1 TRANSAMINASE POLYPEPTIDES Codexis, Inc. (US) 2018-08-01 EP claimed
EP-2385983-B1 TRANSAMINASE POLYPEPTIDES CODEXIS INC (US) 2017-12-20 EP claimed
CN-102797043-B Medicinal molecular fragment library and construction process thereof Tianli (Tianjin) Technology Co., Ltd. (CN) 2015-11-25 CN claimed
CN-102797043-A Medicinal molecular fragment library and construction method thereof CBB NETWORK CO LTD 2012-11-28 CN claimed
EP-2385983-A2 TRANSAMINASE POLYPEPTIDES Codexis, Inc. (US) 2011-11-16 EP claimed
US-D646886-S1 Tip of an umbrella Pro Performance Sports, L.L.C. (US) 2011-10-18 US claimed
US-20100209981-A1 TRANSAMINASE POLYPEPTIDES CODEXIS, INC. (US) 2010-08-19 US claimed
WO-2010081053-A2 TRANSAMINASE POLYPEPTIDES CODEXIS, INC. (US) 2010-07-15 WO claimed
WO-2008035904-A1 METHOD FOR PROCESSING 4-SUBSTITUTED BENZOIC ACID DERIVATIVES HAVING 3, 4-METHYLENE- OR 3,4-ETHYLENEDIOXYBENZENE MOIETY AND THE USE OF THE SAME FOR ANTIAGING COSMETICS AMOREPACIFIC CORPORATION (KR) 2008-03-27 WO claimed
US-7078131-B2 Polymeric sol electrolyte and lithium battery using the same SAMSUNG SDI CO., LTD. (KR) 2006-07-18 US claimed
US-20030059681-A1 Polymeric sol electrolyte and lithium battery using the same SAMSUNG SDI CO., LTD. (KR) 2003-03-27 US claimed
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NEUROGEN CORPORATION 2001-10-18 US claimed
US-6221875-B1 TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL NEUROGEN CORPORATION 2001-04-24 US claimed
US-6117223-A Hot melt inks containing polyketones XEROX CORPORATION (US) 2000-09-12 US claimed
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 US disclosed
US-20260028600-A1 TRANSAMINASE POLYPEPTIDES CODEXIS INC (US) 2026-01-29 US disclosed
US-4097671-A 5-PHENYL-3,6-DIHYDRO-1,3,4-OXADIAZIN-2-ONE, THERMOPLASTIC POLYMER BLOWING AGENT GENERAL ELECTRIC COMPANY (US) 1978-06-27 US disclosed
US-3937841-A AMINO-OXIME COMPOUNDS U.S. PHILIPS CORPORATION (US) 1976-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 KDM4E 1832/4885TSHR 362/4885ATM 3845/4885
US-10052326-B1 Antihepatotoxic agents CYP4X1, CYP2E1, HRH2 KDM4E 615/4885TSHR 1351/4885ATM 4281/4885
US-20260028600-A1 TRANSAMINASE POLYPEPTIDES GOT1, OAT, PEPD KDM4E 3487/4885TSHR 794/4885ATM 760/4885
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NPY1R, NPY2R, NPY5R KDM4E 2474/4885TSHR 117/4885ATM 4355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.